V-7300 Vinblastine, Sulfate Salt, >98%

Synonyms : [29060-LE] [Nincaluicolflastine] [Vinblastine hydrogen sulfate] [Vincaleucoblastine sulfate] [VLB sulfate]

Related Terms : [Alkaban-AQ] [Exal] [Rozevin sulfate] [Velban] [Velsar] [Velbe]

  • Size
  • US $
  • £
  • ¥
  • 10 mg
  • 39
  • 35
  • 30
  • 6,100
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 51
  • 46
  • 40
  • 7,900
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 69
  • 63
  • 54
  • 10,700
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 95
  • 87
  • 74
  • 14,800
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 128
  • 117
  • 100
  • 19,900
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 229
  • 210
  • 180
  • 35,600
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 423
  • 389
  • 332
  • 65,900
  • Add to Cart
  • Out of stock
  • 2 g
  • 756
  • 695
  • 594
  • 117,700
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 909.05
  • C46H58N4O9•H2SO4
  • [143-67-9]
  • M.I. 14: 9982

Storage: Store at or below -20 ºC. Solubility: Poorly soluble in ethanol; soluble in water at 50 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Vinblastine is an antimicrotubule drug that has been used to treat various cancers. Interruption of microtubule structure by antimicrotubule drugs results in induction of tumor suppressor gene p53 and inhibitor of cyclin-dependent kinases p21WAF1/CIP1, and phosphorylation of Bcl-2, which lead to apoptosis in cancer cells. Wang, L.G., et al. "The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review." Cancer Chemother. Pharmacol. 44: 355-361 (1999).
  • Combination chemotherapy with Adriamycin (doxorubicin, please see Cat. No. D-4000, Doxorubicin, Hydrochloride Salt and Cat. No. D-4099, Doxorubicin, Free Base), bleomycin, vinblastine, and dacarbazine (ABVD) is considered the standard of treatment for advanced Hodgkin's lymphoma in North America, providing a good balance of efficacy and toxicity. Hoskin, P.J., et al. "Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244." J. Clin. Oncol. 27: 5390-5396 (2009).
  • Vinblastine chemotherapy is the standard treatment for the patients with aggressive systemic Langerhans cell histiocytosis. Gadner, H., et al. "A randomized trial of treatment for multisystem Langerhans' cell histiocytosis." J. Pediatr. 138: 728-734 (2001).
  • Vinblastine has potent anti-angiogenic properties at picomolar concentrations. The doses of vinblastine needed to cause antiangiogenesis are significantly lower than cytotoxic doses. Vacca, A., et al. "Antiangiogenesis is produced by nontoxic doses of vinblastine." Blood 94: 4143-4155 (1999).
  • Co-targeting of mTOR by temsirolimus (please see Cat. No. T-8040, Temsirolimus) and microtubules by vinblastine in vitro resulted in marked growth inhibition in Huh7 cells and Hep3B cells. The combination of temsirolimus and vinblastine induced a significant and sustained antitumor activity in both Huh7 and Hep3B xenograft models, with significant reduction of tumor vessel density. Zhou, Q., et al. "Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma." Biochem. Pharmacol. 83: 1146-1158 (2012).
  • Weekly vinblastine was demonstrated to be a reasonable alternative to radiation for pediatric patients with low-grade glioma who had failed first-line chemotherapy. The 5-year progression-free survival was shown in this phase II trial to be comparable to results observed with first-line chemotherapy in chemotherapy-naive patients. Bouffet, E., et al. "Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma." J. Clin. Oncol. 30: 1358-1363 (2012).
  • Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin appeared to be a safe, well-tolerated, and effective neoadjuvant chemotherapy regimen for muscle-invasive bladder cancer. Blick, C., et al. "Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder." Cancer 118: 3920-3927 (2012).
  • Related CAS number: 865-21-4 for the free base.
  • STRUCTURE ERRORS ON WIKIPEDIA AND TWO VENDORS' WEBSITES: As of December 21, 2012, the vinblastine structures shown on Wikipedia and at least two vendors' (Santa Cruz and Sigma) web pages are incorrect in one or more ways. (We have not checked most other vendors' vinblastine structures.) Also, the vinblastine structure shown on Chemblink fails to specify the stereochemistry at one asymmetric carbon atom. Finally, the Merck Index Vol. 14 entry for vinblastine shows a dashed bond connecting a nitrogen atom and a symmetrically substituted carbon atom; this appears to be a bond that would not normally be shown as embodying stereochemical information, so our structure shows it as a plain single bond.
  • Vinblastine is the active ingredient in drug products sold under numerous trade names, such as those listed near the top of this page as "Related Terms". These drug products have been approved in at least one country for use in patients with cancer. NOTE: THE VINBLASTINE SOLD BY LC LABORATORIES FOR RESEARCH IS NOT ANY OF THE VINBLASTINE-CONTAINING DRUG PRODUCTS SOLD UNDER VARIOUS TRADE NAMES AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.